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Thymic epithelial tumours (TETs), the most common tumour of the anterior mediastinum, are epithelial neoplasms of the thymus
with a wide spectrum of morphologic features. We retrospectively analysed clinical features of TET and the correlation of World
Health Organisation (WHO) histologic classification and Masaoka staging system with different treatment modalities in 195 patients,
from 1995 to 2005. According to the Masaoka’s staging system, there were 78 (40.0 %) patients with stage I, 38 (19.5%) with stage II,
41 (21.0%) with stage III, 38 (19.5%) with stage IV. All patients were reclassified according to the WHO criteria as follows: Type A
(n¼9, 4.6%), AB (n¼37, 18.9%), B1 (n¼29, 14.8%), B2 (n¼48, 24.6%), B3 (n¼40, 20.5%), C (n¼32, 16.4%). There was a fairly
good correlation between Masaoka staging and WHO histotype (Po0.05). However, in multivariate analysis, the tumour stage and
WHO histotype were two independent factors separately for predicting overall survival (Po0.001, Po0.001, respectively). Thus,
both Masaoka stage and WHO histotype should be considered in risk stratification of therapy for TET patients. Patients with
completely resected types B2, B3 and C and adjuvant radiotherapy (n¼57) had more favourable disease-free and overall survival as
compared with those without adjuvant treatment (n¼20) (P¼0.015, 0.015, respectively). Given that the predominant sites of
recurrence after surgery was pleura/pericardium and lung, and the fact that complete resection was a significant influential factor for
survival at log–rank test, an active investigation of newer treatment strategies such as neoadjuvant treatment to improve the
resectability and development of optimal adjuvant treatment modality is a high priority especially for those with high-risk for
recurrence or in patients with advanced stage disease.
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Thymic epithelial tumours (TETs), the most common tumour of
the anterior mediastinum, are epithelial neoplasms of the thymus
with a wide spectrum of morphologic features (Morgenthaler et al,
1993; Loehrer et al, 2001). The incidence rates of TET are 0.5 in
men and 0.3 in women in the United States per 100000 populations
(Sunpaweravong and Kelly, 2004). One-third to one-half of
patients present with asymptomatic anterior mediastinal mass on
chest radiography, one-third present with local symptoms (e.g.
cough, chest pain, superior vena cava syndrome, and dysphagia)
and one-third are detected during the evaluation of myasthenia
gravis (MG) (Thomas et al, 1999). Approximately 10–15% of
patients with MG will have TET and MG occurs in about 30% of
patients with TET (Kornfeld et al, 1978; Pescarmona et al, 1990;
Wilkins et al, 1991; Blumberg et al, 1995; Thomas et al, 1999;
Sperling et al, 2003).
Owing to the rarity and its morphologic heterogeneity, it is only
recent that provisional consensus on staging and histologic
classifications have been reached. The most widely adopted
staging system is the one proposed by Masaoka in 1981, which
has demonstrated good prognostic relevance. Several groups,
however, have reported several drawbacks of the Masaoka’s
staging system. First, the system does not effectively differentiate
between stages I and II with prognostic significance. Secondly, the
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ssystem is not well-suited for the staging of thymic carcinomas,
which are now categorised as Type C in the World Health
Organisation (WHO) classification of TET. The WHO proposed a
histologic classification system, which subdivided TETs into three
major categories, A, B, and C (thymic carcinoma) in 1999. Since
the introduction of the WHO classification system, several studies
have validated the predictability and good correlation with survival
of TETs. For the WHO classification, some groups have reported
conflicting results according to histotypes: few groups (Okumura
et al, 2002; Nakagawa et al, 2003) concluded that type B3 thymoma
conferred poorer survival compared to type B2, whereas the other
reports (Chalabreysse et al, 2002; Chen et al, 2002; Rieker et al,
2002) showed no significant difference in survival between type B2
and B3 thymomas. Thus, the controversies in classifications of
TETs are unsettled at this time.
We retrospectively analysed the clinical features of TETs and
investigated the prognostic impact of the WHO histotype,
Masaoka’s staging system and the complete resectability in a
series of 195 patients with TETs over a period of 11 years at a
single institution.
PATIENTS AND METHODS
Patients
From 1995 to 2005, 195 patients were pathologically confirmed of
TET at the Samsung Medical Centre. Histologic types of TET were
reviewed by one pathologist specialised in thymic tumours and re-
classified according to WHO criteria as: type A (medullary, spindle
cell), type AB (mixed), type B (cortical) with subtypes B1, B2 and
B3, and type C. The following clinical data were collected from
medical records for each patient: physical examination, surgical
and pathologic reports, imaging and treatment modalities. The
stages were classified according to the Masaoka’s staging system,
which was originally described by surgical stage, that is, stage I,
microscopically encapsulated tumour; stage II, microscopic inva-
sion into capsule; stage III, macroscopic invasion into neighbour-
ing organs; stage IVa, pleural or pericardial dissemination; stage
IVb, lymphatic or haematogenous metastasis (Masaoka et al,
1981).
Treatment
Total thymectomy was defined as the resection of the entire
thymus and mediastinal fatty tissue between both phrenic nerves;
thymomectomy was defined as the resection of thymoma leaving
residual thymic tissue behind; complete resection was defined as
no macroscopic or microscopic residual tumour; and incomplete
resection was defined as the documented macroscopic or
microscopic residual tumour. The postoperative radiation therapy
at the anterior mediastinum was routinely given to the patients
with WHO classification B2 or greater. Before 1999, the indication
for adjuvant radiation therapy was Masaoka stage II or higher, as
well as non-medullary type of Muller–Hermelink classification.
After the surgery, patients were monitored every 3–4 months with
chest CT scan for 2 years, every 6 months for 3 years, and yearly
thereafter.
The cyclophosphamide (PAC) chemotherapy regimen consisted
of PAC 500mgm
 2 (over 1h), doxorubicin 50mgm
 2 (over
30min), and cisplatin 50mgm
 2 (over 1h) administered on day 1
and repeated every 3 weeks. All patients received adequate
hydration (pre- and post-cisplatin) with at least 3l normal saline
in 24h. The recommended anti-emetic schedule comprised 5-HT3
inhibitors and dexamethasone 20mg at the beginning of cisplatin
infusion. In the adjuvant setting, a total of three cycles were
administered post-operatively. In cases of post-operative com-
bined chemotherapy and radiotherapy, radiotherapy was adminis-
tered first and then followed by three cycles of PAC. For palliative
chemotherapy, PAC chemotherapy was given until the documen-
ted progressive disease or up to six cycles.
Radiotherapy was administered with a 6B10 MV linear
accelerator. Adjuvant radiation therapy was given 4–6 weeks after
surgery at a total dose of 54Gy (1.8–2Gy daily, five times/week).
In palliative setting, primary radiation therapy was administered at
a daily dose of 2.5–3Gy for a target dose of greater than 30Gy.
Under the conditions where performance permits and extrathor-
acic disease is controlled, primary radiation therapy up to 50–
60Gy was given. Selected patients with initially unresectable
disease received two to four cycles of PAC chemotherapy and for
patients with stable, partial or complete response to chemotherapy,
patients further received a total radiation dosage of 50–60Gy to
the primary tumour and regional lymph nodes.
Pathology
In each case, one pathologist (J Han) evaluated the haematoxylin-
eosin stained formalin-fixed paraffin sections of surgically resected
thymoma specimens at the time of surgery and blindly reviewed
all the pathologic specimens at the time of this study. All cases
diagnosed before 1999 were initially categorised according to the
Muller–Hermelink classification and reclassified using the WHO
classification for the study. Immunohistochemical staining was
used to distinguish TETs from other mediastinal tumours, using
1:50 CD5 (DAKO, Carpinteria, CA, USA), 1:100 cytokeratin
(DAKO), 1:50 MIC-2 (CD99) (DAKO), 1:100 leucocyte common
antigen (LCA) (DAKO) and 1:40 placental leucocyte alkaline
phosphatase (PLAP) (Novocastra, Newcastle upon Tyne UK).
Statistical analyses
The statistical difference of the average value was examined with
the Student’s t-test. Survival was calculated from the time of
diagnosis to the last follow-up date or death, and survival
curves were obtained by the Kaplan–Meier method; differences
between two curves were assessed using the log–rank test. All the
deaths that were not related to the tumour were considered as
censored observations. All P-values are two-tailed. Prognostic
factors were identified by multivariate analysis, using the Cox
proportional hazards regression model. The following variables
were considered as possible candidate prognostic factors: age, sex,
presence of MG, completeness of the resection, Masaoka stage, and
WHO histologic type. Po0.05 was assumed significant unless
otherwise stated.
RESULTS
Patients characteristics
The characteristics of the 195 patients are shown in Table 1.
Median age was 49 years (range, 18–81). The male/female ratio
was 1.1:1.0. Sixty-one patients (31.3%) had invasion or metastases
to other organs with lung (n¼37, 19.0%) being the most common
site. According to the Masaoka’s staging system, there were 78
(40.0 %) patients with stage I, 38 (19.5%) with stage II, 41 (21.0%)
with stage III, and 38 (19.5%) with stage IV. All patients were
reclassified according to the WHO criteria as follows: Type A
(n¼9, 4.6%), AB (n¼37, 18.9%), B1 (n¼29, 14.8%), B2 (n¼48,
24.6%), B3 (n¼40, 20.5%), C (n¼32, 16.4%) (Table 1). Twenty-
seven patients (13.8%) presented with paraneoplastic syndromes
such as MG, Cushing’s syndrome (n¼2, 1.0%), and haemolytic
anaemia (n¼2, 1.0%). MG was particularly frequent in type B2
TETs with statistical significance as compared to other histotypes
(P¼0.010).
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stages
The association between the WHO histologic subtype and Masaoka
stage was evaluated (Table 2). Two-thirds of the type A, AB, B1,
and B2 TETs were categorised as Masaoka stages I and II. By
contrast, types B3 and C were detected in advanced stages (stages
III and IV) at high frequencies (68.1% at presentation; Po0.01).
There was a significant correlation between Masaoka staging and
WHO histotype (Po0.05) and the proportions of advanced stage
tumours gradually increased from type A to type C. Nevertheless,
there were discordances between Masaoka stages and WHO
histologic subtypes in individual patients (Table 2). Some patients
had advanced Masaoka stage for their benign histotype: five
patients (17.2 %) with B1 tumour type had stage IV disease. In
contrast, others had localised diseases despite of aggressive
histologic subtype: seven patients (21.9%) of type C had stage I
or II diseases, all of whom were treated with R0 resection7adju-
vant therapy.
Association of primary tumour resection with Masaoka
stages and WHO histologic subtypes
One hundred and sixty-one (82.6%). of 195 patients received
complete resections. Complete tumour resection (R0) was achieved
in all the patients with stage I and II TETs and the rate of complete
resection drastically decreased as stage increased (stage I, 100%;
stage II, 100%; stage III, 85.3%; stage IV, 26.3%; Table 3). In all, 91
(56.5%) of the 161 patients with R0 resection received
post-operative therapy such as chemotherapy, radiotherapy or
chemoradiotherapy. The general indications for post-operative
radiotherapy were as follows: positive resection margin, WHO
subtype of B2 or greater, and/or Masaoka stage II or greater. Of the
91 patients who received adjuvant therapy following complete
resections, 78 (85.7%) patients received post-operative radio-
therapy alone. Nine patients with stage III/IV disease received
post-operative systemic chemotherapy or chemoradiotherapy due
to incomplete resections.
According to the WHO histotype, R0 resection was achieved in
all type A and AB TETs and in most of type B1 TETs (93.1%).
Of the 73 patients with type A, AB and B1 who underwent R0
resection, 21 (28.8%) patients received post-operative radio-
therapy. By contrast, complete R0 in type B2, B3, and C TETs
was achieved in only 81.2, 75.0 and 59.3% of cases, respectively
(Table 4). Most of the patients who underwent R1 or R2 resections
received post-operative therapy (chemotherapy or chemo-
radiotherapy). The frequency of the invasive tumours and the
rate of incomplete resection were higher in type B3 and C than
other histologic subtypes (Po0.01).
Association of Masaoka stage and WHO histologic subtype
with survival
Tumour stage and WHO histotype were the most important factors
predicting survival in TET patients. The 5-year survival rates were
96, 100, 71 and 52% for stages I, II, III and IV, respectively (Figures
1 and 2). There was no statistically significant difference in survival
rates between Masaoka stage I and II tumours (P¼0.063) and
between stage III and IV tumours (P¼0.13) (Figure 2). The 5-year
survival rates were 100, 89, 89, 68, and 47% for the types AþAB,
B1, B2, B3, and C, respectively. In multivariate analysis, the tumour
stage and WHO histotype were two independent factors for
predicting overall survival (Po0.001, Po0.001, respectively).
Table 2 Masaoka stage with reference to the WHO histologic
classification system for thymic epithelial tumors
WHO tumour types
Stage A AB B1 B2 B3 C Total
I 5 (6.4) 28 (35.9) 12 (15.4) 20 (25.6) 10 (12.8) 3 (3.8) 78
II 2 (5.3) 9 (2.4) 10 (26.3) 7 (18.4) 6 (15.8) 4 (10.5) 38
III 2 (4.9) 0 (0.0) 2 (4.9) 9 (22.0) 12 (29.3) 16 (39.0) 41
IV 0 (0.0) 0 (0.0) 5 (13.2) 12 (31.6) 12 (31.6) 9 (23.7) 38
Total 9 (4.6) 37 (19.0) 29 (14.9) 48 (24.6) 40 (20.5) 32 (16.4) 195
Abbreviation: WHO¼World Health Organisation.
Table 3 Distribution of treatment modalities according to the masaoka
tumour stage
Masaoka stage
I II III IV Total
n (%) 78 (40.0) 38 (19.5) 41 (21.0) 38 (19.5) 195
Resection type, n (%)
Complete 78 (100.0) 38 (100.0) 35 (85.3) 10 (26.3) 161 (82.5)
Incomplete 0 (0.0) 0 (0.0) 4 (36.4) 7 (63.6) 11 (5.6)
Biopsy only 0 (0.0) 0 (0.0) 2 (8.7) 21 (91.3) 23 (11.8)
Treatment modalities, n (%)
R0 only 43 (55.1) 19 (50.0) 5 (12.2) 3 (7.9) 70 (35.9)
R0+RT 35 (44.9) 17 (44.7) 23 (56.1) 3 (7.9) 78 (40.0)
R0+CT — 2 (5.3) — 3 (7.9) 5 (2.6)
R0+CRT — — 7 (17.1) 1 (2.6) 8 (4.1)
R1/R2+RT — — 2 (8.7) 1 (2.6) 3 (1.5)
R1/R2+CT or CRT — — 2 (8.7) 4 (10.5) 6 (3.1)
CT only — — 1 (2.4) 16 (42.1) 17 (8.7)
CRT only — — 1 (2.4) 5 (13.1) 6 (3.1)
R1/R2 alone — — — 2 (5.3) 2 (1.0)
Abbreviations: CT¼chemotherapy; CRT¼chemoradiation; R0¼R0 resection;
RT¼radiation therapy; R1¼R1 resection; R2¼R2 resection.
Table 1 Clinical findings of patients with TET
Median age (range) 49 years (18–81 years)
Gender ratio (M:F) 103:92 (1.1:1)
Myasthenia Gravis 27 (13.8%)
Involved organ 61 (31.3%)
Lung 37 (19.0%)
Pericardium 27 (13.8%)
Pleural seeding 20 (10.3%)
Innominate vein 16 (8.2%)
Superior vena cava 8 (4.1%)
Pericardial seeding 5 (2.6%)
Mediastinal lymph node 4 (2.0%)
Pulmonary vessels 3 (1.5%)
Phrenic nerve 2 (1.0%)
Chest wall 1 (0.5%)
Aorta 1 (0.5%)
Lung metastasis 1 (0.5%)
Bone metastasis 1 (0.5%)
Liver 1 (0.5%)
Masaoka’s stage
I 78 (40.0%)
II 38 (19.5%)
III 41 (21.0%)
IV 38 (19.5%)
WHO type
A 9 (4.6%)
AB 37 (18.9%)
B1 29 (14.8%)
B2 48 (24.6%)
B3 40 (20.5%)
C 32 (16.4%)
Abbreviation: TET¼thymic epithelial tumours.
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resection
Fifty (66.7%) of 75 patients with WHO type A, AB and B1
thymomas achieved long-term complete remissions with primary
complete resection alone. The administration of adjuvant radio-
therapy in patients with WHO type A, AB, and B1 did not
significantly influence overall survival (P¼0.185) or disease-free
survival (P¼0.962) when compared to those who did not receive
adjuvant therapy during the same period of time. On contrary, in
Table 4 Distribution of treatment modalities according to the WHO subtypes
WHO tumour types
A AB B1 B2 B3 C Total
n (%) 9 (4.6) 37 (18.9) 29 (14.8) 48 (24.6) 40 (20.5) 32 (16.4) 195 (%)
Resection type, n (%)
Complete 9 (100.0) 37 (100.0) 27 (93.1) 39 (81.2) 30 (75.0) 19 (59.3) 161 (82.5)
Incomplete — — 1 (3.4) 4 (8.3) 3 (7.5) 3 (9.4) 11 (5.6)
Biopsy only — — 1 (3.4) 5 (10.4) 7 (17.5) 10 (31.3) 23 (11.8)
Treatment modalities, n (%)
R0 only 6 (66.7) 31 (83.8) 13 (44.8) 14 (29.2) 4 (10.0) 2 (6.3) 70 (35.9)
R0+RT 3 (33.3) 6 (16.2) 12 (41.4) 24 (50.0) 22 (55.0) 11 (34.4) 78 (40.0)
R0+CT — — 2 (6.9) 1 (2.1) 1 (2.5) 1 (3.1) 5 (2.6)
R0+CRT — — — — 3 (7.5) 5 (15.6) 8 (4.1)
R1/R2+RT — — — 1 (2.1) — 2 (6.3) 3 (1.5)
R1/R2+CT or CRT — — — 2 (4.2) 3 (7.5) 1 (3.1) 6 (3.1)
CT only — — 1 (3.4) 4 (8.3) 6 (15.0) 6 (18.8) 17 (8.7)
CRT only — — — 1 (2.1) 1 (2.5) 4 (12.5) 6 (3.1)
R1/R2 alone — — 1 (3.4) 1 (2.1) — — 2 (1.0)
Abbreviations: CT¼chemotherapy; CRT¼chemoradiation; R0¼R0 resection; RT¼radiation therapy; R1¼R1 resection; R2¼R2 resection.
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significantly improved overall survival (P¼0.015) and disease-
free survival (P¼0.015) (Figures 3 and 4).
In 21 stage IV patients treated with primary chemotherapy or
chemoradiotherapy without surgery, the 5-year survival rate was
only 43% with median survival of 57.7 months (95% CI, 3.6–111.8
months). The regimen of chemotherapy used in all these patients
was cisplatin, doxorubicin and PAC. In general, the patients with
complete resection (n¼161) had a significantly better survival
than those without complete resection (n¼34) (Po0.001)
(Figure 3). Of the 161 patients with initial R0 resection, 19 patients
have relapsed after a median follow-up duration of 77.6 months
(45.3–137.3 months). The first recurrent sites after R0 resection
were as follows in order of frequency: pleura (n¼10), lung (n¼4),
local (n¼3), bone (n¼1) and liver (n¼1).
DISCUSSION
In the present study, the histologic subtypes based on the WHO
classification were determined in all of the 195 patients. The most
frequent histologic subtype was type B2 (24.6%), followed by type
B3 (20.5%). The incidence of type AB was slightly lower (37 cases,
18.9%) compared to other studies (Fang et al, 2005; Kim et al,
2005), which reported the proportion of type AB to be 23 to 32%.
MG was encountered in 27 (13.8%) of the 195 TET patients (two
patients of type AB, seven of B1, 10 of B2, and eight of type B3) MG
was significantly more frequent in type B than in types A and AB
(Po0.01). A similar distribution of MG was reported in other
series (Chalabreysse et al, 2002; Chen et al, 2002; Okumura et al,
2002; Nakagawa et al, 2003). Although MG was particularly
frequent in type B2 TETs, there was no difference in survival
between those with and without MG; P40.05). Distant metastases
were distinctly uncommon at initial presentation with this tumour
and the most commonly involved site was pleura followed by
pericardium, lung, bone and liver.
We investigated the correlation between the WHO histologic
subtypes and the Masaoka’s staging system. Thirty (24.4%) of 123
patients with types A, AB, B1 and B2 had advanced disease (stages
III and IV), while 49 (68.1%) of 72 patients with types B3 and C
had advanced disease (Table 2). It has been also reported that most
of type A, AB, B1 and B2 TETs behave in a benign fashion but
type B3 and C have to be considered malignant tumours with a
potential to metastasize (Truong et al, 1990; Hsu et al, 1994). The
long-term outcome of TET patients was significantly correlated to
tumour stage, completeness of surgical resection, and WHO
histotype (Po0.001). The overall survivals of stage III and IV
tumours were significantly poorer than those of stage I and II
tumours (Po0.05). The Masaoka’s staging system, however, did
not significantly differentiate the survival outcome between the
stage I and II patients in accordance with the previous studies
(Pescarmona et al, 1990; Lardinois et al, 2000; Okumura et al, 2002;
Nakagawa et al, 2003). Moreover, despite of clear association
between Masaoka stages and WHO histologic subtypes, good
proportions of patients showed discordances between the two
systems: 17.2% of B1 tumour types with stage IV disease and 21.9%
of type C with stage I/II disease. Since both Masaoka stage and
WHO subtypes are independent prognostic factors for survival in
TETs, these two parameters should be carefully incorporated in
decision-making. Clearly, there is no established guideline for the
discordant cases between the stage and the histologic subtypes. To
enhance treatment outcome, risk stratification therapy of this
subset of TET patients should be sought in future trials.
In the WHO histologic classification, type B3 thymoma is still a
peculiar group that remains controversial in the literature. Several
reports (Okumura et al, 2002; Nakagawa et al, 2003) have revealed
poorer prognosis of type B3 thymoma compared to type B2,
whereas the other reports (Chalabreysse et al, 2002; Chen et al,
2002; Rieker et al, 2002) showed no significant difference in
survival between type B2 and B3 thymomas. Interestingly, when
WHO subtypes were simplified into three groups (A-B2 vs B3 vs
C), the survival curve showed more distinct pattern with type B3
being an intermediate prognostic group (Figure 3). These
simplified three groups might be useful in the future research
and/or therapeutic planning for TETs as reported by other studies
(Rieker et al, 2002; Kim et al, 2005).
Post-operative radiotherapy has long been considered unneces-
sary for stage I TETs after complete resection, although there is
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et al, 1991; Regnard et al, 1996). In view of our data, the adjuvant
radiotherapy did not significantly influence on survival of patients
with type A – B1 when compared to the patients with no adjuvant
radiotherapy. Importantly, patients with completely resected types
B2, B3 and C and adjuvant radiotherapy had more favourable
disease-free and overall survival as compared with those without
adjuvant radiotherapy (Figure 5). Nakahara et al (1988) reported
29% recurrence rate for patients with stage II thymoma after
surgery alone as compared to 8% for those with surgery followed
by adjuvant radiation therapy. Similarly, another study showed a
recurrence rate of 28 vs 8% in stage II patients with post-operative
radiation therapy and those without, respectively (Quintanilla-
Martinez et al, 1994). Most recently, an Italian study demonstrated
no difference in disease-free survival between 32 stage II patients
with surgery alone and 26 patients with surgery followed by
mediastinal radiation therapy (Rena et al, 2007). However, all of
these studies including ours are retrospectively conducted, and
thus, prospective randomised controlled studies are essential to
define the definite role of adjuvant radiotherapy for patients with
stage II or III TETs.
Only 10 out of 38 patients with stage IV TETs achieved R0
resection in our series and most stage IV patients received
chemotherapy alone or combined chemotherapy and radiotherapy.
For the patients who received chemotherapy, all received cisplatin,
doxorubicin, and PAC regimen as the first-line therapy. In a
prospective phase II trial by US co-operative groups (Loehrer et al,
1994; Oshita et al, 1995), the combination of cisplatin, doxo-
rubicin, and PAC showed an overall response rate of 50% with
median survival of 38 months. In our study, 5-year survival rates
were 52% and the median overall survival was 66.1 months (95% CI,
36.6–95.6 months) in 38 patients with stage IV. For the 21 stage IV
patients who were treated with primary chemotherapy or chemo-
radiotherapy without surgical resection, the 5-year OS was only 43%
with median overall survival of 57.7 months (95% CI, 3.6–111.8
months), suggesting that the debulking operation might improve
t h es u r v i v a lo fs t a g eI Vd i s e a s e( Po0.05). However, Myojin and
colleagues reported increased pleural dissemination and recurrence
after surgical exploration for stage III TETs, and questioned the role
of debulking surgery in this setting (Fang et al,2 0 0 5 ) .T h e r e f o r e ,t h e
role of debulking surgery for stage III/IV still remains to be defined.
Patients with incomplete resection had significantly worse
overall survival than patients with a complete resection (Po0.05)
and the WHO subtype was also an important prognostic factor in
patients with incomplete resection. Most patients who underwent
incomplete resection, WHO subtype B3 or C, and stage III or IV,
died of progressive disease, despite multimodality treatment. After
a median follow-up duration of 77.6 months (45.3–137.3 months),
19 of 161 patients have relapsed following R0 resection. Given that
the predominant sites of recurrence after surgery were pleura/
pericardium and lung, and the fact that complete resection was a
significant prognostic factor for survival, focus on novel treatment
strategies such as neoadjuvant treatment to improve the resect-
ability and development of optimal adjuvant treatment modality is
a high priority, especially in patients with high risk of recurrence
or those with advanced stage disease. At present, a precise
treatment algorithm for patients who could potentially benefit
from preoperative chemotherapy and/or radiotherapy is not firmly
established. Given the fact that most of our patients were selected
for preoperative treatment based on CT findings, the superiority of
PET-CT over CT in identifying potential candidates for preopera-
tive treatment needs to be investigated.
Recently, Shin et al (1998) reported that 82% of 12 unresectable
TETs were completely resected after induction chemotherapy, and
another study (Venuta et al, 2003) reported an increased resection
rate and prolonged survival for stage III and IV TETs following
neoadjuvant chemotherapy with cisplatin, epirubicin, and etopo-
side compared to the historical control. In multivariate analysis,
the tumour stage and WHO histotype were two independent
factors for predicting overall survival (Po0.001, Po0.001, respec-
tively). Thus, both Masaoka stage and WHO histotype should be
considered in-risk stratification of therapy for TET patients.
In conclusion, although there was a clear association between
the two systems, the Masaoka stage and WHO histotype were
two independent prognostic factors for survival. Despite some
discordance between the two systems, the two parameters,
therefore, should be considered during decision-making for
therapeutic approaches. Furthermore, patients with WHO sub-
types B3 or C or stage III/IV pursued an aggressive clinical course
despite of multimodality treatment implicating more innovative
therapeutic approach such as neoadjuvant therapy with novel
agents warrants further investigations. Operable patients should be
stratified by risk for recurrence and be given adjuvant treatment
with more tailored therapy.
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